Position in MDGL
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$296,807
-$1,115,949 QoQ
Shares Held
567
-76.6% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Mariner, LLC holds $490,050,155 across 152 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
608,615 | $146,657,956 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
134,614 | $66,866,811 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
100,086 | $62,407,624 | |
| 4 | RPRX |
Royalty Pharma plc
|
693,495 | $38,884,263 | |
| 5 | EXEL |
Exelixis, Inc.
|
313,083 | $17,034,845 | |
| 6 | INCY |
Incyte Corp
|
121,988 | $13,828,559 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
192,607 | $11,020,972 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
28,021 | $8,435,161 |
All Filings in MDGL
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $296,807 | 567 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,412,756 | 2,426 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $835,219 | 1,821 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $469,092 | 1,550 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $624,037 | 1,884 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $538,763 | 1,746 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $636,234 | 2,998 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $809,101 | 2,888 | Shares | Other | 2024-08-13 | |
| 2024-03-31 | $703,115 | 2,633 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $292,001 | 1,262 | Shares | Other | 2024-02-14 | |
| 2022-12-31 | $211,882 | 730 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||